Historical Standards of Care in Metastatic SCAC
A panelist discusses how the historical standard of care for metastatic squamous cell anal carcinoma evolved from cisplatin-based regimens to carboplatin and paclitaxel as the established backbone treatment based on the InterAACT trial, which demonstrated superior progression-free survival and overall survival (20 months vs 12 months) with better tolerability, until recent changes with the POD1UM-303 trial shifted the current standard of care.
Historical Standards of Care in Metastatic SCAC
The treatment landscape for metastatic squamous cell anal carcinoma (SCAC) has undergone significant evolution, with historical approaches giving way to more effective regimens. Previously, cisplatin-based combinations dominated treatment protocols, but the standard of care shifted toward carboplatin and paclitaxel based on updated NCCN guidelines. This transition represented a fundamental change in therapeutic approach, moving away from traditional platinum-based regimens that had limited efficacy and significant toxicity profiles.
The pivotal InterAACT trial served as the foundation for this therapeutic shift, providing crucial comparative data between treatment regimens. This randomized phase 2 study evaluated patients with metastatic or unresectable recurrent squamous cell anal cancer following chemoradiation, comparing carboplatin and paclitaxel against the traditional 5-fluorouracil and cisplatin combination. The trial demonstrated superior progression-free survival with carboplatin and paclitaxel, along with a notable trend toward improved overall survival, showing approximately 20 months vs 12 months for the cisplatin-based regimen. Additionally, the carboplatin and paclitaxel combination offered a more favorable toxicity profile, making it better tolerated by patients.
Despite the InterAACT trial's limitations as a phase 2 study with restricted sample size rather than a definitive phase 3 registration trial, it established carboplatin and paclitaxel as the preferred backbone therapy. Alternative regimens have been explored, including modified DCF (docetaxel, cisplatin, 5-fluorouracil) and FOLFOX protocols, which demonstrated high clinical response rates and favorable outcomes. However, carboplatin and paclitaxel remained the established standard until recent developments, particularly the POD1UM-303 trial, which has now changed the current standard of care for this challenging malignancy.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
